LVLuca Varinelli

Luca Varinelli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luca Varinelli has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A combinatorial culture strategy to develop pseudomyxoma peritonei organoid models

    by Luca Varinelli, Marzia Di Bella, Marcello Guaglio, Davide Battistessa, Federica Pisati, Tommaso Cavalleri, Massimo Milione, Jordi Martínez‐Quintanilla, Patrick T. Caswell, Dario Baratti, et al.

    Background and Objectives: Few preclinical models of pseudomyxoma peritonei (PMP) have been developed, probably due to the tumor's low incidence and its peculiar characteristics of slow growth. Therefore, there is a need to develop more refined PMP models that better reflect its characteristics. The aim of the study is to develop a culture strategy to generate organoid models derived from PMP patient samples.Methods: We followed a strategy based on combinatorial culture conditions that include the different factors essential for PMP growth and that mimic the microenvironment present in the patients.Results: We cultured PMP samples in the presence of the various factors produced by the niche environment of PMP. We obtained 12 PMP organoid models, each of which grows under specific culture conditions. PMP‐derived organoids show long‐term expansion capacity and reproduce the genetic landscape and histological phenotype of the tumor of origin.Conclusion: The organoids we developed faithfully reproduce the key features of PMP disease and will allow us to understand the biology of PMP. With them, we will be able to identify key regulatory networks that support PMP progression, providing a platform for multilevel preclinical testing, identify novel diagnostic biomarkers, and generate novel targets for patient treatments.


  • Open Access

    The nanomechanical fingerprint of colorectal cancer -derived peritoneal metastasis

    by Ewelina Lorenc, Luca Varinelli, Matteo Chighizola, Silvia Brich, Federica Pisati, Marcello Guaglio, Dario Baratti, Marcello Deraco, Manuela Gariboldi, Alessandro Podesta

    Peritoneal metastases (PM) are one of the most common routes of dissemination for colorectal cancer (CRC) and remain a lethal disease with a poor prognosis. The compositional, mechanical and structural properties of the extracellular matrix (ECM) play an important role in cancer development; studying how these properties change during the progression of the disease is crucial to understand CRC-PM development. The elastic properties of ECMs derived from human samples of normal and neoplastic PM in different pathological conditions were studied by atomic force microscopy (AFM); results were correlated to patients’ clinical data and to the expression of ECM components related to metastatic spread. Our results show that PM progression is accompanied by stiffening of ECM as a common feature; spatially resolved mechanical analysis highlighted significant spatial heterogeneity of the elastic properties of both normal and neoplastic ECMs, which show significant overlap in the two conditions. On the micrometre scale, ECMs that are considered normal according to the pathological classification possess stiffer spatial domains, which are typically associated with cancer associated fibroblasts (CAF) activity and tumour development in neoplastic matrices; on the other hand, softer regions are found in neoplastic ECMs on the same scales. Our results support the hypothesis that local changes (stiffening) in the normal ECM can create the ground for growth and spread from the tumour of invading metastatic cells. Mechanical changes correlate well with the presence of CAF and an increase in collagen deposition, which are well known markers of cancer progression. Furthermore, we have found correlations between the mechanical properties of the ECM and patients’ clinical data like age, sex, presence of mutations in BRAF and KRAS genes and tumour grade. Overall, our findings suggest that the mechanical phenotyping of the PM-ECM has the potential for predicting tumour development.

  • Open Access

    Force sensing on cells and tissues by atomic force microscopy

    by Hatice Holuigue, Ewelina Lorenc, Matteo Chighizola, Carsten Schulte, Luca Varinelli, Marcello Deraco, Marcello Guaglio, Manuela Gariboldi, Alessandro Podesta'

    Biosensors are aimed to detect tiny physical and chemical stimuli in biological systems. Physical forces are ubiquitous, being implied in all cellular processes, including cell adhesion, migration, and differentiation. Given the strong interplay between cells and their microenvironment, the extracellular matrix (ECM), the structural and mechanical properties of the ECM play an important role in the transmission of external stimuli to single cells within the tissue. Vice versa, also cells themselves use self-generated forces to probe the biophysical properties of the ECM. ECM mechanics influences cell fate, regulates tissue development and show peculiar features in health and disease conditions of living organisms. Force sensing in biological systems is therefore crucial to dissect and understand complex biological processes, such as mechanotransduction. Atomic Force Microscopy (AFM), which can both sense and apply forces at the nanoscale, with sub-nanoNewton sensitivity, represents an enabling technology and a crucial experimental tool in biophysics and mechanobiology. In this work, we report on the application of AFM to study of biomechanical fingerprints of different components of biological systems, such as the ECM, the whole cell, and cellular components, like the nucleus and the glycocalyx. We show that physical observables like the (spatially resolved) Young’s modulus of elasticity of ECMs or cells, and the effective thickness and stiffness of the glycocalyx, can be quantitatively characterised by AFM. Their modification can be correlated to changes of the microenvironment, physio-pathological conditions, or gene regulation.


  • Open Access

    Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production

    by Angela Mogavero, Maria Valeria Maiorana, Susanna Zanutto, Luca Varinelli, Fabio Bozzi, Antonino Belfiore, Chiara C. Volpi, Annunziata Gloghini, Marco A. Pierotti, Manuela Gariboldi

    Metformin is a widely used and well-tolerated anti-diabetic drug that can reduce cancer risk and improve the prognosis of certain malignancies. However, the mechanism underlying its anti-cancer effect is still unclear. We studied the anti-cancer activity of metformin on colorectal cancer (CRC) by using the drug to treat HT29, HCT116 and HCT116 p53−/− CRC cells. Metformin reduced cell proliferation and migration by inducing cell cycle arrest in the G0/G1 phase. This was accompanied by a sharp decrease in the expression of c-Myc and down-regulation of IGF1R. The anti-proliferative action of metformin was mediated by two different mechanisms: AMPK activation and increase in the production of reactive oxygen species, which suppressed the mTOR pathway and its downstream targets S6 and 4EBP1. A reduction in CD44 and LGR5 expression suggested that the drug had an effect on tumour cells with stem characteristics. However, a colony formation assay showed that metformin slowed the cells’ ability to form colonies without arresting cell growth, as confirmed by absence of apoptosis, autophagy or senescence. Our finding that metformin only transiently arrests CRC cell growth suggests that efforts should be made to identify compounds that combined with the biguanide can act synergistically to induce cell death.


  • Open Access

    MIF/CD74 axis is a target for novel therapies in colon carcinomatosis

    by Fabio Bozzi, Angela Mogavero, Luca Varinelli, Antonino Belfiore, Giacomo Manenti, Claudio Caccia, Chiara C. Volpi, Galina V. Beznoussenko, Massimo Milione, Valerio Leoni, et al.

    Strategies aimed at obtaining a complete cytoreduction are needed to improve long-term survival for patients with colorectal cancer peritoneal carcinomatosis (CRC-pc). We established organoid models from peritoneal metastases of two naïve CRC patients. A standard paraffin inclusion was conducted to compare their 3D structure and immunohistochemical profile with that of the corresponding surgical samples. RNA expression levels of the CRC stem cell marker LGR5 was measured by in situ hybridization. The secretome of organoids was profiled by mass spectrometry. Energy homeostasis of organoids was interfered with 4-IPP and metformin. Biochemical and metabolic changes after drug treatments were investigated by western blot and mass spectrometry. Mitochondria impairment was evaluated by electron microscopy and mitotraker staining. The two organoids recapitulated their corresponding clinical samples in terms of 3D structure and immmunoistochemical profile and were positive for the cancer stem cells marker LGR5. Proteomic analyses of organoids highlighted their strong dependence on energy producing pathways, which suggest that their targeting could be an effective therapeutic approach. To test this hypothesis, we treated organoids with two drugs that target metabolism acting on AMP-activated protein kinase (AMPK), the main regulator of cellular energy homeostasis, which may act as metabolic tumour suppressor in CRC. Organoids were treated with 4-IPP, an inhibitor of MIF/CD74 signalling axis which activates AMPK function, or metformin that inhibits mitochondrial respiratory chain complex I. As a new finding we observed that treatment with 4-IPP downregulated AMPK signalling activity, reduced AKT phosphorylation and activated a JNK-mediated stress-signalling response, thus generating mitochondrial impairment and cell death. Metformin treatment enhanced AMPK activation, decreasing the activity of the anabolic factors ribosomal protein S6 and p4EBP-1 and inducing mitochondrial depolarization. We provide evidence that the modulation of AMPK activity may be a strategy for targeting metabolism of CRC-pc organoids.


  • Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone

    by Chiara Maura Ciniselli, Maida De Bortoli, Elena Taverna, Luca Varinelli, Sara Pizzamiglio, Silvia Veneroni, Chiara Bonini, Rosaria Orlandi, Paolo Verderio, Italia Bongarzone

    Objective: Hepcidin-25 production is stimulated by systemic inflammation, and it interferes with iron utilization, leading to anemia. This study aimed to investigate the relationships between the p...


  • 4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas

    by Luca Varinelli, Dario Caccia, Chiara Costanza Volpi, Claudio Caccia, Maida De Bortoli, Elena Taverna, Ambra V Gualeni, Valerio Leoni, Annunziata Gloghini, Giacomo Manenti, et al.

    Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that is over-expressed in several human neoplastic cells. When MIF binds its receptor (CD74) and co-receptor (CD44), it initiates signaling cascades that orchestrate cell proliferation and survival, and it can directly modulate the activity of AMPK. These activities indicate that MIF potentially regulates cell survival and metabolism. We found that MIF was primarily co-expressed with CD74 in 16 out of 23 papillary thyroid carcinoma (PTC) and in all the 27 available anaplastic thyroid carcinoma (ATC) biopsy samples. MIF and CD74 were co-expressed in TPC-1 and HTC-C3 cell lines. The selective MIF inhibitor, 4-iodo-6-phenylpyrimidine (4-IPP), blocked MIF/CD74 internalization, activated JNK, and dose-dependently inhibited proliferation inducing apoptosis and mitotic cell death. In two CD74-negative cell lines, NIM-1 and K1, 4-IPP treatment partially reduced proliferation. Coordinated MIF and CD74 expression appeared to confer in tumor cells the plasticity necessary to escape cell cycle regulation, metabolic changes, and stress conditions. MIF/CD74 signaling removal made cells susceptible to apoptosis and mitotic cell death. This finding suggests a possible avenue for targeting DNA endoreduplication, thus preventing the proliferation of therapy-resistant cell subpopulations. This study highlights MIF/CD74 axis as an important player in the biology of aggressive thyroid neoplasms.


  • Proteomics and lymphomas

    by Luca Varinelli, Italia Bongarzone